26 / 60
26
Scientific programme
Friday, 29 May 2015
P-10-006 Efficacy and tolerability of lisdexamfeta-
mine (LDX) in children and adolescents
with Autism Spectrum Disorders (ASD)
and Attention-Deficit/Hyperactivity Dis
order (ADHD) symptoms
W. Jaimes-Albornoz, Spain
A. Ballesteros-Prado
P-10-007 Cost-effectiveness of guanfacine extended-
release for the treatment of children
and adolescents with Attention Deficit
Hyperactivity Disorder (ADHD) in the UK
A. Joseph, Switzerland
J. Xie, E. Wu, V. Sikirica
P-10-008 Interaction between dopaminergic
genotypes and frontostriatal volumes
predicting methylphenidate response in
Attention-Deficit/Hyperactivity Disorder
B.-N. Kim, Republic of Korea
J. W. Kim, S.-C. Cho
P-10-009 Factors related to a lower response to
methylphenidate in a continuous perfor-
mance test (CPT) evaluation
N. Lourenço, Portugal
J. Boavida Fernandes, M. Jerónimo, C.
A. Alfaiate, M. Almeida, S. Nogueira, M.
J. Seabra Santos, J. Boavida Fernandes
P-10-010 Milnacipran and atomoxetine in the
treatment of adolescents with Attention-
Deficit/Hyperactivity Disorder
I. Martsenkovsky, Ukraine
M. Inna
P-11
Guided Poster Tour
16:00–17:30
Hall 2 – Poster Area
Pharmacological treatment –Children and
adolescents II
Chairs:
J. Buitelaar, The Netherlands
P-11-001 A phase 2 pharmacokinetic study of a
modified release formulation of dextro-
amphetamine following evening admin-
istration to adolescents and children with
ADHD
D. Quinn, Canada
T. Bode, B. DeSousa, B. Incledon, A. McLean,
D. Lickrish
P-11-002 Sleep problems in ADHD youth before and
during treatment with methylphenidate
and atomoxetine
M. Stein, USA
M. Garison, A. Hart, J. Newcorn
P-11-004 Outcome of ADHD treatment in young
people age 14 – 18 years
I. Takon, United Kingdom
S. Ozer, A. Khan, R. Beets, M. Atherton
P-11-005 Randomized, double-blind, active- and
placebo-controlled trials of lisdexamfe-
tamine dimesylate in adolescents with
Attention-Deficit/Hyperactivity Disorder
J. Newcorn, USA
P. Nagy, A. Childress, G. Frick, B. Yan,
L. Politza, S. Pliszka
P-11-006 ADHD medication prescribing among
young people with ADHD in the clinical
practice research datalink 2005-2013:
Analysis of time to cessation
T. Newlove-Delgado, United Kingdom
T. Ford, W. Hamilton, K. Stein, O. C. Ukou
munne
P-11-007 Objective evaluation of ADHD in special
needs settings-explicating clinical out-
comes
S. Perera, United Kingdom
J. Kaleyias
P-11-008 Digital follow-up for children with ADHD
E. Posener, Israel
P-11-009 Association of DAT1 gene and clock gene
(T3111C) genotypes, family functioning,
parental psychopathology and treatment
response in ADHD adolescents
F. Delapena, Mexico
D. Guizar, L. Palacios, C. Cruz, V. Perez